<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37195">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622321</url>
  </required_header>
  <id_info>
    <org_study_id>BH29884</org_study_id>
    <secondary_id>2015-002866-21</secondary_id>
    <nct_id>NCT02622321</nct_id>
  </id_info>
  <brief_title>A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Patients With Inhibitors (HAVEN 1)</brief_title>
  <official_title>A Randomized, Multi-Center, Open-Label Phase III Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Patients With Inhibitors (HAVEN 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multicenter, open-label study will evaluate the safety, efficacy and pharmacokinetics
      of prophylactic emicizumab treatment in patients previously treated with episodic or
      prophylactic bypassing agents. Episodic bypassing agent patients will be randomized in a 2:1
      fashion to receive emicizumab prophylaxis (Arm A) versus no prophylaxis (Arm B) and will be
      stratified across Arms A and B according to the number of bleeds they experienced over the
      last 24 weeks prior to study entry (less than [&lt;] 9 or greater than or equal to [&gt;=] 9
      bleeds); Arm B patients will have the opportunity to switch to emicizumab prophylaxis after
      24 weeks on-study. Prophylactic bypassing agent patients will switch to emicizumab
      prophylaxis (Arm C) from the start of the trial; enrollment will be extended for 24 weeks
      after the last patient has enrolled in Arms A or B or until approximately 50 patients have
      enrolled in Arm C, whichever occurs first. Episodic bypassing agent patients who previously
      participated in a Non-Interventional Study BH29768 but were unable to enroll in Arms A or B
      prior to their closure will have the opportunity to enroll in Arm D until 24 weeks after the
      last patient has enrolled in Arms A or B or until approximately 35 patients have enrolled in
      Arm D, whichever occurs first. Like patients in Arms A and C, Arm D patients will receive
      emicizumab prophylaxis from the start of the trial. All patients will continue to receive
      standard of care/background treatment with their usual episodic bypassing agent therapy to
      treat breakthrough bleeds, as needed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of bleeds over time</measure>
    <time_frame>24 weeks or discontinuation from the study, whichever occurrs first (up to approximately 26 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of all bleeds (whether treated or not treated by coagulation factors) over time</measure>
    <time_frame>24 weeks or discontinuation from the study, whichever occurs first (up to approximately 26 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in number of all bleeds over time</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in number of bleeds over time</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in number of joint bleeds over time</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in number of target joint bleeds over time</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemophilia-Specific Quality of Life (Haem-A-QoL) (adults)</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemo-QoL-Short Form (adolescents)</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) score</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration (Ctrough) of emicizumab</measure>
    <time_frame>(Pre-dose) Every week during Weeks 1-4, every 2 weeks during Weeks 5-8, every 4 weeks during Weeks 9-24, every 8 weeks during Weeks 25-48, every 12 weeks thereafter while on emicizumab until the end of the study (approximately 108 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Arm A: Episodic Treatment+Study Drug (Emicizumab Prophylaxis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with inhibitors who received episodic treatment with bypassing agents prior to study entry will be randomized to receive emicizumab prophylaxis when they start the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Episodic Treatment (No Prophylaxis)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with inhibitors who received episodic treatment with bypassing agents prior to study entry will be randomized to continue episodic bypassing agent treatment when they start the trial; they will have the opportunity to switch to emicizumab prophylaxis after 24 weeks on-study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Study Drug (Emicizumab Prophylaxis)+Episodic Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with inhibitors who received prophylactic treatment with bypassing agents prior to study entry will receive emicizumab prophylaxis when they start the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: Study Drug (Emicizumab Prophylaxis)+Episodic Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Episodic bypassing agent patients who previously participated in a Non-Interventional Study BH29768 but were unable to enroll in Arms A or B prior to their closure will have the opportunity to enroll in Arm D, in which they will receive emicizumab prophylaxis when they start the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emicizumab</intervention_name>
    <description>Emicizumab will be administered subcutaneously at a dose of 3 mg/kg/week for 4 weeks followed by 1.5 mg/kg/week up to the end of the study.</description>
    <arm_group_label>Arm A: Episodic Treatment+Study Drug (Emicizumab Prophylaxis)</arm_group_label>
    <arm_group_label>Arm B: Episodic Treatment (No Prophylaxis)</arm_group_label>
    <arm_group_label>Arm C: Study Drug (Emicizumab Prophylaxis)+Episodic Treatment</arm_group_label>
    <arm_group_label>Arm D: Study Drug (Emicizumab Prophylaxis)+Episodic Treatment</arm_group_label>
    <other_name>ACE910; RO5534262</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 12 years or older at the time of informed consent

          -  Body weight &gt;=40 kg at the time of screening

          -  Diagnosis of congenital hemophilia A of any severity and documented history of
             high-titer inhibitor (i.e., &gt;=5 Bethesda Units [BU])

          -  Documentation of treatment with episodic or prophylactic bypassing agents for at
             least the last 24 weeks

          -  &gt;=6 bleeds in the last 24 weeks prior to screening (if on an episodic bypassing agent
             regimen) or &gt;=2 bleeds in the last 24 weeks prior to screening (if on a prophylactic
             bypassing agent regimen)

          -  Adequate hematologic function

          -  Adequate hepatic function

          -  Adequate renal function

          -  For women who are not postmenopausal or surgically sterile: agreement to remain
             abstinent or use single or combined highly effective contraceptive methods

        Exclusion Criteria:

          -  Inherited or acquired bleeding disorder other than hemophilia A

          -  Ongoing (or plan to receive during the study) immune tolerance induction therapy or
             prophylaxis with Factor VIII (FVIII), with the exception of patients who have
             received a treatment regimen of FVIII prophylaxis with concurrent bypassing agent
             prophylaxis

          -  Previous (in the past 12 months) or current treatment for thromboembolic disease
             (with the exception of previous catheter-associated thrombosis for which
             antithrombotic treatment is not currently ongoing) or current signs of thromboembolic
             disease

          -  Other conditions (e.g., certain autoimmune diseases) that may increase the risk of
             bleeding or thrombosis

          -  History of clinically significant hypersensitivity associated with monoclonal
             antibody therapies or components of the emicizumab injection

          -  Known human immunodeficiency virus (HIV) infection with CD4 count &lt;200
             cells/microliter within 24 weeks prior to screening

          -  Use of systemic immunomodulators (e.g., interferon or rituximab) at enrollment or
             planned use during the study, with the exception of antiretroviral therapy

          -  Concurrent disease, treatment, or abnormality in clinical laboratory tests that could
             interfere with the conduct of the study or that would, in the opinion of the
             investigator or Sponsor, preclude the patient's safe participation in and completion
             of the study or interpretation of the study results

          -  Planned surgery (excluding minor procedures such as tooth extraction or incision and
             drainage) during the study

          -  Receipt of Emicizumab in a prior investigational study An investigational drug to
             treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug
             administration A non-hemophilia-related investigational drug within last 30 days or 5
             half-lives, whichever is shorter An investigational drug concurrently

          -  Unwillingness to use highly effective contraception methods for the specified
             duration in the protocol (females only, unless required otherwise by the local health
             authority)

          -  Clinically significant abnormality on screening evaluations or laboratory tests that,
             in the opinion of the investigator, may pose an additional risk in administering
             study drug to the patient

          -  Pregnancy or lactation, or intent to become pregnant during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BH29884 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>PA</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <zip>10904</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt/M.</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>MÃ¶rfelden-Walldorf</city>
        <zip>64546</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Aichi</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyogo</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanagawa</city>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu-shi</city>
        <zip>807-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nara</city>
        <zip>634-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>61-828</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Costa Rica</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 4, 2016</lastchanged_date>
  <firstreceived_date>December 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
